Q125 Earnings Beat Boosts Confidence in Oncology and Cardio Drugs
TLDR Novartis reported Q1 2025 EPS of $2.28, beating expectations by 7.55%. Revenue reached $13.23 billion, surpassing estimates…
Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots
Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company…